

Pharmacy Drug Policy Checklist

POLICY NAME Alopecia Areata Products POLICY # 3236P

Criteria

Coverage Criteria	
	Diagnosis of severe alopecia areata defined as Severity of Alopecia Tool (SALT) score of ≥50 indicating at least 50% hair loss
	Age 18 years or older for Olumiant, age 12 years or older for Litfulo
	Current alopecia episode lasting at least 6 months without spontaneous regrowth
	Prescribed by or in consultation with a dermatologist (skin doctor)
	 Documented trial and failure to one of the following therapies or clinical contraindication to all: Oral (by mouth), intralesional (injection) or topical (applied to skin) corticosteroid Topical (applied to the skin) immunotherapy (such as diphenylcyclopropenone or squaric acid dibutyl ester) Conventional oral (by mouth) immunosuppressant (such as methotrexate or azathioprine)
Exclusion Criteria – Any of the following prevents coverage	
	Not covered for use in patients with a diffuse hair loss pattern or other forms of alopecia such as androgenic alopecia or chemotherapy (cancer treatment) induced hair loss
	Cannot be used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants